Home › Mieloma multiplo › Michigan
Studi clinici su Mieloma multiplo nello stato di Michigan
26 studi su Mieloma multiplo cercano partecipanti presso sedi nello stato di Michigan.
Città nello stato di Michigan
- Detroit19 studi
- Ann Arbor10 studi
- Grand Rapids8 studi
- Warren4 studi
- Lansing4 studi
- Flint3 studi
- Waterford3 studi
- Saginaw3 studi
- Livonia3 studi
Testo ufficiale dello studio (inglese)
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- START Midwest /ID# 279035, Grand Rapids
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT07409246A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Karmanos Cancer Institute, Detroit
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07518186A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- University of Michigan Health System, Ann Arbor
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT04634552A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Barbara Ann Karmanos Cancer Institute - Detroit, Detroit
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07393282A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- University of Michigan, Ann Arbor
- Henry Ford Cancer - Detroit Brigitte Harris Cancer Pavilion, Detroit
- Cancer And Hematology Centers of Western Michigan PC, Grand Rapids
- e altri 2
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05552222A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Barbara Ann Karmanos Cancer Institute, Detroit
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05201781TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Trinity Health Ann Arbor Hospital, Ann Arbor
- Henry Ford Health Saint John Hospital, Detroit
- Genesys Hurley Cancer Institute, Flint
- e altri 7
In reclutamentoFase 2
Età 12 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT02693535A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- University of Michigan Health System - Ann Arbor /ID# 271536, Ann Arbor
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT06953960A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Henry Ford Health System, Detroit
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT06980480A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Grand Rapids
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT05714839AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Research Site, Ann Arbor
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT06106945Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- e altri 36
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT04566328A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Karmanos Cancer Institute, Detroit
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT06292780AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Ann Arbor
- Research Site, Detroit
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Detroit
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 ago 2026 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- START Midwest, Grand Rapids
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 12 ago 2026 · NCT07280013A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Karmanos Cancer Institute, Detroit
- START Midwest, Grand Rapids
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 ago 2026 · NCT07284758A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Karmanos Cancer Institute, Detroit
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 lug 2026 · NCT05137054Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
- University of Michigan, Ann Arbor
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 lug 2026 · NCT06057402Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
- Karmanos Cancer Institute, Detroit
- KCI at McLaren Greater Lansing, Lansing
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 26 giu 2026 · NCT06107738Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Saint Joseph Mercy Hospital, Ann Arbor
- Bronson Battle Creek, Battle Creek
- Saint Joseph Mercy Brighton, Brighton
- e altri 51
In reclutamentoFase 3
Tutte le età · Tutti i sessi · Aggiornato il 10 giu 2026 · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Henry Ford St. John Hospital, Grosse Pointe Woods
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 giu 2026 · NCT05243797Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Karmanos Cancer Institute, Detroit
- START Midwest, Grand Rapids
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 mag 2026 · NCT06433947A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
- Karmanos Cancer Institute, Detroit
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 mag 2026 · NCT05828511A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Ann Arbor
- GSK Investigational Site, Detroit
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 apr 2026 · NCT06679101Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
- Karmanos Cancer Institute, Detroit
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 26 ago 2025 · NCT06908629Fonte: ClinicalTrials.gov, dati recuperati il 3 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.